RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of SOX or mFOLFOX6 as neoadjuvant chemotherapy in
patients with resectable rectal cancer, and to identify the more promising regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Clinical Research Support Center Kyush
Treatments:
Antibodies Fluorouracil Hepatitis C Antibodies Immunoglobulins Leucovorin Oxaliplatin Tegafur